Material
T he graft-versus-leukemia effect and graft-versus-host disease (GVHD) after HLA-matched stem cell transplantation (SCT) are mainly driven by alloimmune reactivities against minor histocompatibility Ags (mHags) (1) . mHags are HLA-restricted polymorphic peptides derived from genes with differential tissue distribution (2) . The ubiquitously expressed mHags (e.g., H-Y) are the prime in situ targets of GVHD (3) . In contrast, the hematopoiesis-restricted mHags might be used for boosting the graft-versus-leukemia effect, with low risk for GVHD (1) . The mHag HA-1 is only expressed by human normal and malignant hematopoietic cells (2) and by solid tumors (4) . The antitumor efficacy of HA-1-specific CTLs is demonstrated by two observations. First, the emergence of HA-1-specific (and HA-2-specific) CTLs coincides with remissions in hematological malignancies after donor lymphocyte infusions (5) . Second, HA-1-specific CTLs significantly delay human leukemia progression (6) and destroy human breast cancer metastases in immunodeficient mice (7) . The optimal clinical approach to target HA-1 is still unclear. In vitro generation of HA-1-specific CTLs for adoptive transfer is possible, but it is too laborious for routine clinical practice (8) . Alternatively, patients could be vaccinated with "off-the-shelf " HA-1 peptides to stimulate HA-1-specific CTLs, which are emerging after allogeneic SCT. The HA-1 protein comprises two alleles resulting from a single amino acid polymorphism [histidine (H) ↔ arginine (R)] (9) . Only the HA-1 H allele (but not the HA-1 R allele) results in immunogenic T cell epitopes (in HLA-A2 and -B60) (1, 10) . Thus, HLA-matched/HA-1-mismatched SCT results in strong T cell responses by the HA-1 RR donor against hematopoietic cells of the HA-1 HR or HH patient. HA-1 vaccines to boost these responses are based on the immunogenic HA-1 H epitope. Indications for the optimal design of HA-1 peptide vaccines can be deduced from therapeutic cancer vaccine studies in the autologous setting. Most studies are based on exact HLA class I-binding peptides derived from the amino acid sequences of tumorassociated Ags (TAAs) (11, 12) . These peptides reflect exactly the T cell epitope of usually 9-10 aa and are subsequently named short peptides (SPs). Clinical studies repeatedly showed that vaccination with SPs can induce detectable immune responses (11, 12) . Nevertheless, the clinical responses to cancer peptide vaccination are still poor. Animal data showed that s.c. administration of SPs derived from the adenovirus type 5 early region 1 (Ad5E1) induces immunological tolerance (13) (14) (15) , whereas vaccination with ex vivo Ad5E1 SP-loaded dendritic cells (DCs) leads to immunity (15) . The induction of tolerance by the s.c.-administered Ad5E1 SPs was explained by systemic peptide spreading, leading to peptide presentation by nonprofessional APCs distant from the s.c. injection site (e.g., in the lung) (13) (14) (15) . Moreover, SPs can bind directly to MHC class I molecules of circulating APCs (e.g., B and T cells), which are capable of peptide presentation in lymph nodes all over the body (16) . Thus, systemic presentation of SPs in the absence of proper costimulatory molecules may cause suboptimal CTL responses or even tolerance.
Animal studies showed that C-and/or N-terminal extension of OVA-derived SPs with natural flanking sequences can improve the T cell response, particularly T cell priming (16, 17) . The following arguments were attributed to the superiority of these so-called "long peptides" (LPs). First, LPs cannot bind directly to MHC molecules. Instead, they require processing before presentation of the immunogenic epitope. The superior Ag-processing capacity of professional APCs focuses the LP presentation on DCs. Second, restriction of OVA-derived LP presentation to the regional lymph nodes draining the coadministered adjuvants may guarantee Ag presentation on optimally activated APCs. Finally, in vivo presentation of OVA-derived LPs is prolonged compared with SPs as the result of a still-unknown mechanism (16) .
HA-1 SP-based vaccination studies were initiated recently (K. van Besien and A. Ganser, personal communication). Meanwhile, the animal data described above prompted us to study the impact of HA-1 peptide extension on Ag presentation. We compared the in vitro characteristics of a selected HA-1 LP and SP with regard to the optimal requirements for their presentation by DCs, their presentation efficiency and persistency on DCs, and the peptide-presenting cell types in detail. We discuss the impact of our findings on HA-1 peptide vaccination after allogeneic SCT.
Materials and Methods

Donor material
Peripheral blood was collected from healthy donors. PBMCs were isolated by Ficoll density gradient centrifugation. Approval was obtained from the Leiden University Medical Center (LUMC) review board. Informed consent was provided according to the Declaration of Helsinki. HA-1 typing of donors was performed as previously described (18) .
Peptides
Short 9-mer peptides and long 30-mer peptides were synthesized on an automated multiple-peptide synthesizer (Syro; MultiSynTech, Witten, Germany), purified, and characterized by analytical reversed-phase HPLC. None of the mass spectrometry patterns of the LPs showed any signals for the SP. Peptides were dissolved at 25 mg/ml in 100% DMSO and stored at 220˚C. Peptides were further diluted to a concentration of 1 mg/ml in PBS and used in the assays in the indicated concentrations.
Effector cells
HLA-A2-restricted HA-1-specific CTL lines and the HA-1-specific CTL clone 1.7 were generated with PBMCs from healthy donors, as previously described (8) , via weekly stimulation of PBMCs with autologous activated DCs pulsed with HA-1 peptide for 3 h. The percentage of HA-1-specific CTLs in the CTL lines was determined by staining with allophycocyaninlabeled tetramers, as described earlier (19) .
Stimulator cells
HLA-A p 0201 pos EBV-transformed lymphoblastoid cell lines (LCLs) were generated in our laboratory. EBV LCLs and the TAP-deficient mutant cell line T2 were cultured in IMDM supplemented with 5% FCS. Fibroblasts (kind gift of Dr. Nicola Annels, Department of Pediatrics, LUMC, Leiden, The Netherlands) were cultured in 10% FCS/IMDM. Mock GFP and the TAP inhibitor ICP-47-GFP (kindly provided by Dr. E. Wiertz, Department of Medical Microbiology, LUMC)-transduced EBV LCLs were described earlier (20) . Monocyte-derived DCs were generated by isolation of CD14 + cells from PBMCs using CD14 microbeads (Miltenyi Biotec, Utrecht, The Netherlands). The CD14 + cells were cultured in RPMI 1640 supplemented with 8% FCS, 800 U/ml GM-CSF (Invitrogen, Breda, The Netherlands), and 250 U/ml IL-4 (Invitrogen). On days 2 and 4, medium was refreshed, and immature DCs were frozen on day 6. After thawing, DCs were cultured in 24-well plates in the presence of GM-CSF and IL-4 for 24 h. Subsequently, DCs were activated with 1 mg/ml CD40 ligand (CD40L) trimers (R&D Systems, Abingdon, U.K.) or with human CD40L-transfected murine fibroblasts (tCD40L; kindly provided by Dr. C van Kooten, Department of Nephrology, LUMC). The fibroblasts were irradiated (90 Gy) and used at a concentration of 1 3 10 5 cells/well. T cells and B cells were isolated from frozen CD14-depleted PBMCs by negative isolation to avoid activation of the cells (T cell and B cell isolation kit II; Miltenyi Biotec). Before the experiment, T cells, B cells, and monocytes were cultured in 24-well plates in X-VIVO 15 (Lonza, Verviers, Belgium) for 24 h to allow recovery from thawing.
Incubation with peptide and inhibitors
Stimulator cells were harvested by thorough resuspension and washed with PBS. Peptide incubation of 5 3 10 5 cells was performed in 500 ml X-VIVO 15 or AimV (Life Technologies, Breda, The Netherlands) (Fig. 2B ) at 37˚C in 15-ml tubes, unless stated otherwise. During incubation, tubes were placed horizontally to prevent a high density of cell accumulation at the bottom of the tube. For subsequent assays, DCs, monocytes, T cells, and B cells were irradiated (30 Gy) to reduce the background proliferation of stimulator cells. HA-1 RR EBV LCLs, T2 cells, and fibroblasts were fixed with glutaraldehyde, because irradiation was mostly insufficient for these cells to suppress background proliferation. Before fixation, stimulator cells were washed three times with PBS. Fixation was performed with glutaraldehyde 0.05% (Sigma-Aldrich, Zwijndrecht, The Netherlands) in PBS for 60 s. The reaction was stopped with 0.2 M glycine in PBS for 30 s, and cells were washed three times with PBS. HA-1 H target cells were irradiated with 30 Gy (DCs) or 100 Gy (EBV LCLs) because glutaraldehyde fixation destroyed CTL recognition of the natural epitope. Proteasome dependency was tested by stimulator cell incubation with the proteasome inhibitors epoxomicin (20 and 2 mM) or lactacystin (40 and 4 mM) (Alexis Biochemicals, Raamsdonksveer, The Netherlands) for 2 h at 37˚C. Subsequently, peptides were added and incubated for 3 h.
Proliferation test
The HA-1-specific CTL clone 1.7 was cultured for 3 d in 10% human serum in IMDM and 120 IU/ml IL-2 (Chiron, Amsterdam, The Netherlands). Before the proliferation assay, target cells were washed three times with PBS and resuspended in 10% human serum in IMDM. 
Chromium release assay
In vitro cytotoxicity was measured in standard [ 51 Cr]-release assays, as described earlier (8) . In short, 2500 51 Cr-labeled target cells were incubated with dilutions of effector CTLs for 4 h; supernatants were harvested for gamma counting using the following formula: percentage of specific lysis = (experimental release 2 spontaneous release)/(maximal release 2 spontaneous release) 3 100%.
Statistics
Different groups were compared by a Mann-Whitney U test using SPSS 16.0 (SPSS, Chicago, IL). A p value ,0.05 was considered statistically significant.
Results
Selection of the HA-1 LP
The length of the 30-aa HA-1 LP was chosen based on the capability of 25-35 mer LPs to induce HPV-specific immune responses in murine (16, 17, 21) and clinical studies (22, 23) . Six HA-1 LPs of the HA-1 protein sequence containing the HA-1 epitope were selected (Fig. 1A) . Only LPs with sequences flanking the N and C terminus of the epitope were used to maximize the demand for peptide processing before HA-1 epitope presentation. Subsequently, the LPs' capacities to stimulate HA-1-specific CTL proliferation after peptide loading on CD40-activated monocytederived DCs were compared. Peptide loading was performed under serum-free conditions to minimize the risk for peptide degradation by serum proteases. All six HA-1 LPs induced HA-1-specific CTL proliferation to various extents, as determined by [ 3 H]thymidine uptake. The HA-1 LP 123-152 induced by trend the greatest level of HA-1-specific CTL proliferation (Fig. 1B) . Therefore, HA-1 LP 123-152 was used in all subsequent experi-ments and referred to as the HA-1 LP. The HA-1 nonameric peptide 137-145 comprising the exact HA-1 T cell epitope was referred to as HA-1 SP.
HA-1 LP presentation is processing dependent
The dose dependency of HA-1 LP presentation was tested by titrating HA-1 LP and SP to HLA-A2 + /HA-1 RR EBV LCLs (derived from HLA-A2 + donors homozygous for the nonimmunogenic HA-1 R allele) and TAP-deficient T2 cells and incubating for 3 h at 37˚C. HA-1 LP required 2-3 log levels more peptide than HA-1 SP to induce equal HA-1-specific CTL proliferation ( Fig. 2A) . Next, the impact of the peptide incubation time and temperature on HA-1 LP and SP presentation was studied. The time dependency of HA-1 LP presentation was tested by incubation of HLA-A2 + /HA-1 RR EBV LCLs with HA-1 LP or SP for 1, 3, and 24 h at 37˚C. Presentation of HA-1 LP reached its maximum after 3 h (Fig. 2B) , whereas presentation of HA-1 SP was comparable for all tested incubation times. The temperature dependency of HA-1 LP presentation was tested by incubation of HLA-A2 + /HA-1 RR EBV LCLs with HA-1 LP and SP at 4˚C and 37˚C. HA-1 LP presentation was largely abrogated at 4˚C, whereas SP was presented equally well at 4˚C and 37˚C (Fig. 2B) . Next, the relevance of cell-released enzymes for the presentation of HA-1 LPs was investigated. As described in detail below, T and B cells presented HA-1 SP but very little LP. Thus, we incubated these HA-1 LP nonpresenting T and B cells with HA-1 LP or SP in the presence of medium conditioned for 24 h by LP-presenting cells (activated DCs or T2 cells). The presence of conditioned The Journal of Immunologymedium did not result in HA-1 LP presentation by T and B cells (Fig. 2C) . Thus, HA-1 LP presentation most likely results from cellular enzymatic processing and not from extracellular degradation.
HA-1 LP presentation is proteasome and TAP independent
Presentation of endogenous HA-1 in EBV LCLs and DCs from donors positive for the immunogenic HA-1 H allele was inhibited by incubation with the proteasome inhibitors epoxomicin (Fig.  2D, upper panel) and lactacystin (Supplemental Fig. 1B) . In contrast, incubation of DCs and EBV LCLs from donors homozygous for the nonimmunogenic HA-1 R allele with proteasome inhibitors did not hamper HA-1 LP or SP presentation (Fig. 2D,  lower panel) . Thus, HA-1 LP presentation is, in contrast to endogenous HA-1 presentation, proteasome independent. Similar results were obtained for T2 cells and fibroblasts (Supplemental Fig. 1A, 1B) . The TAP inhibitor ICP-47, which is capable of abrogating the presentation of endogenously expressed HA-1 in HA-1 H EBV LCLs, did not reduce the presentation of HA-1 LP or SP (Fig. 2E) . Combined with the HA-1 LP presentation by TAPdeficient T2 cells ( Fig. 2A) , these results suggest the TAP independency of HA-1 LP presentation.
HA-1 LP is best presented by activated DCs
The impact of DC activation on HA-1 peptide presentation was investigated. DCs were activated with CD40L trimers or tCD40Ls for 24 h and incubated with 1 mM HA-1 LP or SP for 3 h in 24-well plates. Flow cytometry revealed a marked upregulation of the costimulatory molecules CD80 and CD86 and of HLA-A2 after DC activation (data not shown). CD40L trimer-and tCD40L-activated DCs induced a 4-6-fold greater and statistically different (p = 0.001 and p = 0.004, respectively) level of HA-1-specific CTL proliferation compared with nonactivated DCs (Fig. 3A) . Next, we tested whether HA-1 LP presentation can be further enhanced by prolonging the peptide incubation time or by changing the sequence of DC activation and peptide loading. tCD40Ls were added to nonactivated DCs (group A) or 24 h before (group B), simultaneously with (group C), or 6 h after (group D) the addition of peptides. Again, activated DCs induced 3-5-fold greater (A-B, p = 0.009; A-C, p = 0.003; A-D, p = 0.079) levels of HA-1-specific CTL proliferation compared with nonactivated DCs. The magnitude of HA-1-specific CTL proliferation was not statistically different between the tested sequences of CD40 activation and peptide administration (B-C, p = 0.631; C-D, p = 0.497; B-D, p = 0.661). Overall, DCs presented HA-1 LP by trend best after 3 h of peptide incubation subsequent to 24 h of DC activation (Fig. 3B) . Thus, DCs were peptide loaded for 3 h after 24 h of activation in all subsequent experiments.
HA-1 LP-pulsed DCs expand polyclonal HA-1-specific CTLs
Polyclonal HA-1-specific CTL lines were generated by weekly stimulation of PBLs from two healthy HA-1 RR blood donors with HA-1 LP-and SP-pulsed autologous DCs. Both donors were known to be immunized against HA-1 H . A dose of 10 mM for HA-1 LP was selected, because HA-1-specific CTL proliferation reached its plateau at this peptide dose (Fig. 4A) . HA-1 SP was applied at 1 mM (i.e., the standard dose used in our protocols for HA-1-specific CTL generation) (19) . After three stimulations, the percentage of HA-1 tetramer-stained cells reached 7.2 and 9.8% for HA-1 LP-stimulated CTL lines and up to 51 and 3.1% for HA-1 SPstimulated CTL lines (Fig. 5A) . Expansion of total HA-1 tetramerstained cells after four stimulations was comparable for HA-1 LP-and SP-stimulated CTL lines (Fig. 5B) . The HA-1 LP-and SP-stimulated CTL lines from both donors lysed hematopoietic cells from HA-1 H individuals (including leukemia cells), but not from HA-1 RR individuals (Fig. 5C ). Thus, HA-1 LP-and SP-loaded DCs can expand high-avidity polyclonal HA-1-specific CTLs. The decays of HA-1 LP and SP peptide presentation on DCs are comparable Next, persistence of HA-1 LP and SP presentation on activated DCs was compared. DCs loaded in 24-well plates with titrated amounts of peptides were placed in 96-well plates, and HA-1-specific CTLs or anti-HLA-A2-specific CTLs were added immediately (0 h) or after 24, 48, 72, 96, 120, 144, or 168 h. No change in proliferation of the anti-HLA-A2-specific CTL clone was observed when stimulated by HA-1 LP-and SP-loaded DCs, suggesting that the overall Ag-presenting capacity was stable. HA-1 LP and SP presentation declined after peptide loading of DCs, and the HA-1 LP and SP dose-response curves remained largely parallel throughout the observation period (Fig. 6, Supplemental Fig. 2A, 2B) . Thus, the decays of HA-1 LP and SP presentation on DCs are comparable.
HA-1 LP presentation is skewed toward DCs
The capacity of activated DCs and other APCs to present HA-1 LP and SP was tested in peptide-titration experiments. T cells, B cells, and monocytes from HA-1 RR donors were isolated from PBMCs. Purity of T cells, B cells, and monocytes was .90%, as determined by flow cytometry for CD3, CD19, and CD14 (data not shown). HA-1 LP or HA-1 SP was titrated to activated DCs, T cells, B cells, nonadherent monocytes, and adherent fibroblasts and incubated for 3 h. Subsequently, HA-1-specific CTL proliferation in response to peptide-loaded target cells was determined. Activated DCs required 2-3 log levels more HA-1 LP than SP to induce equal HA-1-specific CTL proliferation (Fig.  4A ). Fibroblasts loaded with peptide under adherent conditions presented HA-1 LP and SP only slightly less efficiently than DCs (Fig. 4A) . B cells and nonadherent monocytes induced little HA-1-specific CTL proliferation after loading with the maximal dose of 100 mM HA-1 LP (Fig. 4A, upper panel) . HA-1 LP-loaded T cells did not induce HA-1-specific CTL proliferation (Fig. 4A, upper panel) . In contrast, SP-loaded DCs, fibroblasts, T cells, B cells, and monocytes induced considerable HA-1-specific CTL proliferation (Fig. 4A, lower panel) . Overall, HA-1 LP presentation is more restricted to DCs than HA-1 SP presentation. Interestingly, adherent monocytes and fibroblasts presented HA-1 LP better than nonadherent monocytes and fibroblasts (data not shown), suggesting that cell adherence may affect the extent of HA-1 LP presentation.
Hematopoietic cells of HA-1
H individuals stimulate HA-1-specific CTL proliferation Host chimeric cells frequently persist in patients after allogeneic HLA-matched SCT and may present the immunogenic host HA-1 H allele to the transplanted HA-1 H -negative donor-immune system. Therefore, we tested the capacity of T cells, B cells, and monocytes of an HA-1 H individual to stimulate the proliferation of HA-1-specific CTLs. We found that, particularly, HA-1 H naturally expressing monocytes effectively stimulate HA-1-specific CTL proliferation (Fig. 4B) .
Discussion
Processing dependency of HA-1 LP presentation Our data show that presentation of the selected HA-1 LP resulted from cellular enzymatic processing, because its presentation was time-, temperature-, and cell-type-dependent and not inducible via the supernatant of HA-1 LP-presenting cells. Presentation of HA-1 LP was 2-3 log levels less efficient than HA-1 SP, which is in accordance with previous reports on LPs derived from the TAAs NY-ESO-1 LP (24), Melan-A, and gp100 (25) . It is unclear whether insufficient Ag uptake or processing is responsible for the low presentation of LPs in HLA class I. Ags accessing the cytosol are usually processed via the conventional pathway of endogenous molecules. These Ags undergo proteasomal cleavage and are translocated by TAP to the endoplasmic reticulum, where they associate with HLA class I molecules before transport to the cell surface. Ags not accessing the cytosol are processed via alternative, typically proteasome-and/or TAPindependent pathways (26) (27) (28) . Previous reports showed that TAAderived LPs can be presented proteasome dependently [e.g., NY-ESO-1 (24) or Melan-A (25)] or independently [e.g., gp100 (25) ] and TAP independently [e.g., NY-ESO-1 (24)]. In our study, HA-1 LP presentation was, irrespective of the cell type (DCs, EBV LCLs, T2 cells, and fibroblasts) and in contrast to the endogenous HA-1, not repressed by proteasome inhibitors. Moreover, the TAP inhibitor ICP47 did not repress HA-1 LP presentation by EBV LCLs. Thus, our results indicate that HA-1 LP is processed via an alternative pathway.
Potential vaccine characteristics of HA-1 LPs
We found that HA-1 LP presentation by DCs can be strongly increased via CD40 activation, which is described to enhance cross-presentation of soluble Ags (29) . These data are in support of the concept that LPs favor presentation in the context of optimal costimulation (16, 17, 30) . Nevertheless, the improved presentation of HA-1 LP by activated DCs is also surprising, because DC maturation downregulates endocytosis (31) . However, similar observations were made previously for gp100 LP (but not Melan-A LP), which is best presented by LPS-matured DCs (25) , and for exogenous OVA, which is best presented in MHC class I by murine DCs after maturation with TLR 3 and 9 agonists (32) .
Further evaluation of the cell types presenting HA-1 peptides revealed that circulating T cells, B cells, and nonadherent monocytes hardly present HA-1 LP, whereas they effectively present HA-1 SP. This finding is in accordance with previous results showing that OVA-derived LPs are not presented by T cells or B cells isolated from local lymph nodes (16, 17) . Consequently, HA-1 LP presentation is indeed skewed toward activated DCs. However, fibroblasts also presented HA-1 LP very well. Thus, HA-1 LPs can also be presented in the absence of optimal costimulation. This finding is important, because systemic spreading of peptides and subsequent presentation in a low-costimulatory context (e.g., in the lungs) was linked to the tolerance induction in the Ad5E1 system in vivo (13) (14) (15) . What determines the capacity of a cell to present HA-1 LPs remains unclear. Apart from the intrinsic Ag-presenting capacity of cells, circumstances like prolonged in vitro culture in the presence of growth factor-rich FCS (as for monocyte-derived DCs, EBV LCLs, and fibroblasts) or cell adherence (as for adherent monocytes and fibroblasts) might affect HA-1 LP presentation. These issues are subjects for further studies.
Finally, the superior vaccine efficacy of LPs over SPs has also been attributed to the, mechanistically unclear, longer persistence of LP presentation in vivo (16) . DCs from draining lymph nodes very rapidly lose Ag presentation after isolation, which points toward an extracellular depot, rather than toward Ag storage within the DCs (16) . However, a recent study also demonstrated slower decays of Melan-A and gp100 LP presentation compared with the respective SPs on the cellular level (25) . In contrast, our study revealed that the decays of HA-1 LP and SP presentation are comparable. Remarkably, HA-1 SP was still detectable up to 7 d after DC loading with 100 mM peptide. This extremely long presentation might result from the high HLA-binding affinity of HA-1 and its low dissociation rate from HLA (33, 34) . These features may stabilize HA-1 peptides better on DCs than TAA peptides, which frequently have a low HLA-binding affinity (35, 36) . Overall, the phenomenon of prolonged LP presentation on the cellular level cannot be generalized and might differ between Ags of different HLA-binding affinity, as well as between peptide sequences. Future studies on HA-1 LPs may involve linkage of LPs to TLR agonists (37) or Abs (38) to facilitate receptormediated Ag uptake and to increase the extent and duration of HA-1 LP presentation.
HA-1 LPs in the context of allogeneic SCT
Activated DCs loaded with HA-1 LPs stimulated HA-1-specific CTL clones and effectively expanded polyclonal HA-1-specific CTL lines (from sensitized healthy donors), showing killing of leukemia cells in vitro. Notably, donor mHag CTLs emerging after allogeneic SCT are polyclonal memory T cells (5) already primed in the donor during pregnancy (39, 40) and/or in response to the patient's mHags after allogeneic SCT. Earlier studies revealed a restricted TCR usage for recognition of HLA-A2/HA-1 H by in vivo and in vitro HA-1 SP-induced HA-1-specific CTLs (41, 42) . Interestingly, the HA-1 tetramer + cells isolated from HA-1 LPstimulated CTL lines also used the same TCR b variable chain TCRBV7-9 (Supplemental Fig. 3 ). These data suggest that HA-1 LPs might be promising vaccines to stimulate the in vivo pre-existing HA-1-specific CTLs capable of eradicating residual leukemia cells.
Yet, several questions regarding the superiority of HA-1 LPs over SPs as vaccines after allogeneic SCT remain. First, the low presentation efficiency of HA-1 LPs in vitro might be further aggravated in vivo because it is unknown when DCs, after allogeneic SCT, are functional enough to process and to present HA-1 LPs (43) . Also, the general efficiency of alternative Ag-processing pathways, as shown for HA-1 LP in our study, in vivo is unknown (27) . Second, our results show that HA-1 LP presentation is more restricted to activated DCs than HA-1 SP presentation, which may improve the quality of HA-1 LP-induced immune responses compared with SP-induced immune responses. However, in the potential HA-1 peptide vaccination strategy after allogeneic SCT, one needs to consider the transplanted donor hematopoiesis homozygous for the nonimmunogenic HA-1 R allele and the host hematopoiesis positive for the immunogenic HA-1 H allele. Depending on the conditioning, graft composition, and other factors, residual host chimeric cells frequently persist for many months after allogeneic SCT (44) . Consequently, host-derived hematopoietic cells with less costimulatory capacity than DCs present HA-1 H systemically. This assumption is underlined by our finding that endogenous HA-1 H is well presented by circulating monocytes. Therefore, it seems questionable whether LP-mediated skewing of HA-1 peptide presentation to DCs may be beneficial over SPs in the allogeneic SCT setting. Finally, the reported greater efficacy of LPs in animal studies was particularly related to priming of naive T cells against neoantigens (16, 17, 21) . However, mHag-specific immune responses after allogeneic SCT in humans are largely secondary immune responses. Therefore, the respective animal studies might not be predictive of the immunological situation after allogeneic SCT in humans.
In conclusion, careful balancing of the advantages and disadvantages of using HA-1 LPs or SPs as peptide vaccine does not provide clear guidance about which type of peptide may lead to optimal results after allogeneic SCT. Therefore, the optimal peptide for boosting HA-1-specific CTLs may only be determined in clinical trials directly comparing LPs with SPs.
